Denosumab filed for large but competitive osteoporosis indication in Japan
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has filed for the approval in Japan of the antibody denosumab (licensed from Amgen) in what stands to become its second indication, postmenopausal osteoporosis.